According to the current analysis of Emergen Research, the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%. Metastatic urothelial carcinoma is one of the leading cancer-related death across the globe. Metastasis is the leading cause of cancer-related treatment failure and cancer-related...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian